On June 23, Health 160 rose 8.84% in regular trading, trading at HK$12.48/share, with turnover of approximately HK$13.86 million.

The rally was driven by a dual catalyst: Zhipu AI announced its flagship model GLM-5.2 under MIT open-source license supporting localized deployment, directly addressing compliance and cost barriers for public hospital AI adoption; meanwhile, the CSRC chairman recently announced expansion of the STAR Market fifth listing standard to AI, explicitly naming future health and medical AI agents as key priorities for new productive forces.

For Health 160, these catalysts amplify its existing fundamentals. The company's 160AI Hospital platform has cumulatively signed 120 public medical institutions including 66 top-tier hospitals, ranking first among China's AI hospital operation service providers per Frost & Sullivan. The high-margin digital healthcare segment (gross margin approximately 80.9%) continues to drive profitability improvement, with the company achieving its first full-year adjusted breakeven in the prior fiscal year at RMB 4.06 million adjusted net profit on RMB 652 million revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)